Sign In
Buy FLGT
$16.55
-3.66 (-18.11%)
At Close: Jul 31, 2026
NEWTOWN, Pa., May 28, 2025 (GLOBE NEWSWIRE) -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Fulgent Genetics, Inc. (“Fulgent”) (NASDAQ: FLGT)
NEW YORK, NY / ACCESS Newswire / May 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
12:00pm, Tuesday, 27'th May 2025
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ:FLGT). Such investors are ad
Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Investors to Inquire about Securities Investigation
10:00am, Tuesday, 27'th May 2025
NEW YORK, NY / ACCESS Newswire / May 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulgent Genetics, Inc. ("Fulgent" or "the Company") (NAS
FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm
09:19pm, Saturday, 24'th May 2025
LOS ANGELES--(BUSINESS WIRE)--FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
09:00am, Saturday, 24'th May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ:FLGT). Such investors a
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Fulgent Genetics, Inc. (“Fulgen
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
09:46am, Thursday, 22'nd May 2025
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT). Such inves
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
09:00am, Wednesday, 21'st May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ:FLGT). Such investors a
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT
06:06pm, Tuesday, 20'th May 2025
NEW YORK , May 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. ("Fulgent" or the "Company") (NASDAQ: FLGT). Such investors are advised
Wolf Haldenstein Adler Freeman & Herz LLP is investigating Fulgent Genetics, Inc
08:11am, Monday, 19'th May 2025
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION NEW YORK , May 19, 2025 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder righ
Wolf Haldenstein Adler Freeman & Herz LLP is investigating Fulgent Genetics, Inc
08:48am, Friday, 16'th May 2025
PLEASE CLICK HERE TO PROVIDE YOUR CONTACT INFORMATION
Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript
12:27pm, Friday, 02'nd May 2025
Fulgent Genetics, Inc. (FLGT) Q1 2025 Earnings Call Transcript
Fulgent Genetics, Inc. (FLGT) Q1 Earnings and Revenues Beat Estimates
09:10am, Friday, 02'nd May 2025
Fulgent Genetics, Inc. (FLGT) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.19 per share. This compares to loss of $0.01 per share a year ag
Fulgent Reports First Quarter 2025 Financial Results
07:00am, Friday, 02'nd May 2025
EL MONTE, Calif.--(BUSINESS WIRE)--Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a th
